Defence to Collaborate with Native Ads for Marketing Campaign
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce it has entered into a service agreement with Native Ads Inc. ("Native Ads"), pursuant to which Native Ads will provide a marketing campaign for a total retainer of up to US$250,000,...
2023-09-22 4:00 PM EDT
Defence's Broad and Versatile Accum(R) Technology Platform Focus on Cancer Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies, is pleased to announce its continuation to bringing innovative strategies aimed at targeting various indications related to immune-oncology. Whether using an antibody, cell-based vaccine or small molecule therapeutics, the common denominator in all of Defence's development...
2023-09-12 3:15 AM EDT
Defence's Innovative Therapeutics Featured on Viewpoint with Dennis Quaid
Vancouver, British Columbia--(Newsfile Corp. - September 5, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce that Viewpoint, the educational television show distributed nationally and hosted by veteran actor Dennis Quaid, is gearing up with content providers to share information regarding breakthroughs in...
2023-09-05 3:15 AM EDT
Defence Successfully Completes the First Milestone of Its Collaboration Agreement with Orano
Vancouver, British Columbia--(Newsfile Corp. - July 18, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") is pleased to announce that it has successfully reached the first milestone established in the Collaboration Agreement with Orano Support SAS on behalf of Orano SA ("Orano"), a world-renowned multinational company, headquartered in Chatillon, France, to develop the next generation radio-immunoconjugates using Defence's intracellular...
2023-07-18 3:15 AM EDT
RETRANSMISSION: Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology
Vancouver, British Columbia--(Newsfile Corp. - July 5, 2023) - Defence Therapeutics Inc. ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid. This exciting partnership aims to explore breakthroughs in biotechnology and highlight the transformative potential of cutting-edge therapeutics. Defence Therapeutics Inc., with its commitment...
2023-07-05 3:15 AM EDT
Defence and Viewpoint with Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology
Vancouver, British Columbia--(Newsfile Corp. - July 4, 2023) - Defence Therapeutics Inc. ("Defence" or the "Company") a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies is pleased to announce its collaboration with Viewpoint with Dennis Quaid. This exciting partnership aims to explore breakthroughs in biotechnology and highlight the transformative potential of cutting-edge therapeutics. Defence Therapeutics Inc., with its commitment...
2023-07-04 3:15 AM EDT
Defence Patent Portfolio at the Forefront of Success
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company") is a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies. Sitting at the core of its innovative technologies is the proprietary Accum™-based platform, which Defence is harnessing to develop innovative therapeutics and prophylactics against cancers and infectious diseases. Although...
2023-06-28 10:30 AM EDT
Defence's Proprietary Accum(TM) Technology for Delivery of CRISPR/Cas Genome-Editing Complexes Patent Application Published
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce the publication of its new international (PCT) patent application demonstrating the effectiveness of Defence's AccumTM-based technology to intracellularly deliver a wide variety of cargoes while...
2023-06-20 3:15 AM EDT
Defence Manufacturing of AccuTox(TM) CGMP Final Drug Product Optimization for Its Phase I Clinical Trial at City of Hope
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it reached the final stages of its AccuTOXTM Chemistry, Manufacturing and Controls ("CMC") in preparation to IND filling for its Phase I clinical trial to treat melanoma patients at...
2023-06-16 3:15 AM EDT
Defence Begins Testing Its Arm Vaccine Against Pancreatic Cancer
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it mandated Transbiotech Biotechnology Research and Transfer Center to initiate testing its cellular anti-cancer ARM vaccine against deadly pancreatic cancer. Using the AccumTM...
2023-06-06 3:15 AM EDT
Defence Announces Additional and Final Exercises of Warrants for Gross Proceeds of Over $2.3 Million
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that, in addition to the previously announced proceeds of $5,494,375 on March 17, 2023, it has received additional proceeds in the aggregate amount of $2,308,625 from the exercise of...
2023-05-26 5:00 PM EDT
Breakthrough Results: Defence's Arm Vaccine Cured 100% of Animals with Pre-Established Lymphoma
Vancouver, British Columbia--(Newsfile Corp. - May 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of a pre-clinical study evaluating the therapeutic potency of a second-generation ARM vaccine targeting solid tumors. The AccumTM technology holds a promising...
2023-05-24 3:15 AM EDT
Defence's Successful AccuTOX(TM) Pre-Clinical Efficacy Study Complete Ready For Phase I IND Filing
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce the successful completion of all required pre-clinical efficacy studies regarding its AccuTOXTM program. AccuTOXTM is one of Defence's most advanced research and development program....
2023-05-02 3:15 AM EDT
USPTO Grants Trademark Registration for Defence Therapeutics(R)
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2023) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted registration for its trademark DEFENCE THERAPEUTICS®. This trademark is granted under registration number 7,033,299 for products such as "vaccines for human...
2023-04-27 3:15 AM EDT
Defence Granted US Patent with Broad Coverage on Accum(TM)-based Vaccine Enhancer Platform Technology
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugates ("ADCs"), is pleased to announce the issuance of its US patent no. 11,612,651 by the United States Patent and Trademark Office (USPTO). The US patent broadly covers Defence's AccumTM-based...
2023-04-24 3:15 AM EDT
Defence's Novel Accum(TM)-mRNA Vaccine Now Administered for Testing on Cancer
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it commenced comparing the therapeutic potency of "naked" to AccumTM-linked mRNA in immunocompetent mice. This first set of studies aims to validate a recently achieved milestone...
2023-04-17 3:15 AM EDT
RETRANSMISSION: Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins
Vancouver, British Columbia--(Newsfile Corp. - April 11, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it successfully established a strategy conjugating mRNA molecules to AccumTM. The potency of this modified product will now be compared to "naked" mRNA administered as vaccines in...
2023-04-11 3:15 AM EDT
Defence Breakthrough: Successfully Engineered Accum(TM)-mRNA Vaccine Creating a New Vaccine Platform. The in vivo Accum(TM)-mRNA Cancer Vaccine Program Begins
Vancouver, British Columbia--(Newsfile Corp. - April 10, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that it successfully established a strategy conjugating mRNA molecules to AccumTM. The potency of this modified product will now be compared to "naked" mRNA administered as vaccines in...
2023-04-10 5:00 PM EDT
Defence to Complete a Final Pre-Clinical Study Prior to IND Filings for the AccuTOX(TM) Phase I Cancer Trial at the City of Hope National Medical Center and Beckman Research Institute
Vancouver, British Columbia--(Newsfile Corp. - March 28, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies is pleased to announce that it is currently conducting a final pre-clinical study aimed at validating the efficacy of AccuTOXTM combined to immune-checkpoint inhibitors akin to the clinical design to be used...
2023-03-28 3:15 AM EDT
Defence Therapeutics Announces Exercise of Warrants for Gross Proceeds of over $5 Million
Vancouver, British Columbia--(Newsfile Corp. - March 17, 2023) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that over the course of the last 6 months the Company has received over $5 million in gross proceeds from the exercise of warrants, pursuant an early warrant exercise program (the "Early Warrant Exercise Program")....
2023-03-17 5:00 PM EDT